148 related articles for article (PubMed ID: 15283887)
1. Continuing trends in pathological stage migration in radical prostatectomy specimens.
Derweesh IH; Kupelian PA; Zippe C; Levin HS; Brainard J; Magi-Galluzzi C; Myles J; Reuther AM; Klein EA
Urol Oncol; 2004; 22(4):300-6. PubMed ID: 15283887
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
3. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
4. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
5. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
Sankin A; Tareen B; Lepor H
Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
7. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration.
Jhaveri FM; Klein EA; Kupelian PA; Zippe C; Levin HS
J Clin Oncol; 1999 Oct; 17(10):3167-72. PubMed ID: 10506614
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
[TBL] [Abstract][Full Text] [Related]
9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
10. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
11. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
12. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
13. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
14. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
15. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
Patel DA; Presti JC; McNeal JE; Gill H; Brooks JD; King CR
J Clin Oncol; 2005 Sep; 23(25):6157-62. PubMed ID: 16135482
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
18. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
[TBL] [Abstract][Full Text] [Related]
19. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
